Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNF472 in ESRD Patients on Haemodialysis: Effect on Cardiovascular Calcification
2016-002834-59Phase 2Completed
- Sponsor
- Sanifit Therapeutics
- Start
- Sep 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SNF472 in end-stage kidney disease (ESKD) and arterial calcification (3 arms), sponsored by Sanifit Therapeutics. Primary endpoint: Change in coronary artery calcium volume score. Started Sep 2016; status: completed.
02
Drugs
SNF472
03
Conditions
end-stage kidney disease (ESKD)arterial calcification
Beyond the preview
Go deeper on 2016-002834-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002834-59.